title: Engineering an antiplatelet adhesion layer on an electrospun scaffold using porcine endothelial progenitor cells.
abstract: In coronary artery bypass graft interventions, luminal thrombosis is one of the greatest challenges for polymeric grafts with a luminal diameter less than 4 mm. Previously, we reported the fabrication of a highly porous micro/nanofibrous electrospun scaffold and demonstrated the excellent biocompatibility of the scaffolding materials with human endothelial cells. In this study, we explored the engineering of an antithrombotic layer on the scaffold's lumen within 48 h, using peripheral blood-derived porcine endothelial progentior cells (EPC). Flow cytometric results showed that they were CD31(-) but highly CD34(+) and CD105(+) , suggesting the primitive nature of these freshly isolated EPC. The vast majority of EPC readily took up low density lipoprotein, confirming their endothelial phenotype. These EPC also exhibited a strong proliferation capacity on the scaffold for up to 11 days. A confluent layer could be easily engineered within 24 h, which successfully prevented platelet adhesion, a critical step in the cascade of thrombotic events. We concluded that this scaffold could afford a convenient means for the regeneration of a functional cardiovascular endothelium shortly after implantation. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.
authors.affiliation: Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors.forename: Xing
authors.initials: X
authors.lastname: Zhang
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Xu
authors.forename: Vinoy
authors.initials: V
authors.lastname: Thomas
authors.forename: Susan L
authors.initials: SL
authors.lastname: Bellis
authors.forename: Yogesh K
authors.initials: YK
authors.lastname: Vohra
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D018952:Antigens, CD34 / Q000096:biosynthesis; D001672:Biocompatible Materials / Q000737:chemistry; D002448:Cell Adhesion / Q000187:drug effects*; D000071063:Endoglin; D042783:Endothelial Cells / Q000166:cytology*; D004730:Endothelium, Vascular / Q000166:cytology; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism; D010973:Platelet Adhesiveness; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000096:biosynthesis; D011956:Receptors, Cell Surface / Q000096:biosynthesis; D013234:Stem Cells / Q000166:cytology*; D013552:Swine; D013927:Thrombosis; D013997:Time Factors; D054457:Tissue Scaffolds / Q000737:chemistry*
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D001672:Biocompatible Materials; C064206:ENG protein, human; D000071063:Endoglin; D005343:Fibrinolytic Agents; D008077:Lipoproteins, LDL; D010975:Platelet Aggregation Inhibitors; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011956:Receptors, Cell Surface